Continue reading OncoGenex (OGXI): Biotech Targets Cancer Treatments

OncoGenex (OGXI): Biotech Targets Cancer Treatments originally appeared on BloggingStocks on Wed, 06 Apr 2011 10:00:00 EST. Please see our terms for use of feeds.

This post is one in a series in which more than 60 newsletter advisors share their Top Stock Picks for 2011. This special report is courtesy of TheStockAdvisors.com.

"For a number of reasons, my top stock pick for 2011 is Affymetrix (AFFX)," says biotech sector specialist Nate Pile.

The editor of Nate's Notes explains, "This small company based in Santa Clara, CA, develops, manufactures, sells, and services equipment and consumables used in the life sciences industry to do what is know as 'high throughput genetic screening.'

Continue reading Top Picks 2011: Affymetrix (AFFX)

Top Picks 2011: Affymetrix (AFFX) originally appeared on BloggingStocks on Fri, 07 Jan 2011 15:00:00 EST. Please see our terms for use of feeds.

This post is one in a series in which more than 60 newsletter advisors share their Top Stock Picks for 2011. This special report is courtesy of TheStockAdvisors.com.

"We are recommending Aastrom Biosciences (ASTM) as our top stock recommendation for 2011 because we believe that they are the clear leader in the regenerative stem cell space," notes biotech sector specialist John McCamant.

The editor of The Medical Technology Stock Letter explains, "The company is focused on the development of autologous cellular therapies for the treatment of cardiovascular diseases utilizing its Tissue Repair Cell (TRC) technology.

Continue reading Top Picks 2011: Aastrom Biosciences (ASTM)

Top Picks 2011: Aastrom Biosciences (ASTM) originally appeared on BloggingStocks on Fri, 31 Dec 2010 09:00:00 EST. Please see our terms for use of feeds.

"After releasing their 3Q financials. the stock price at Isis Pharmacueticals (ISIS) perked up as their large cash position and deep pipeline have attracted some new investors," notes biotech expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "When investors investigate the ISIS story and all its parts, they come away with an appreciation for all the potential long-term value being created at the company.

Continue reading Isis (ISIS): 'Deep Pipeline, Long-Term Value'

Isis (ISIS): 'Deep Pipeline, Long-Term Value' originally appeared on BloggingStocks on Fri, 17 Dec 2010 13:00:00 EST. Please see our terms for use of feeds.

"Gilead Sciences (GILD) is a top-rated stock on both our fundamental and technical screens; indeed, the biotech world tends to run on its own steam, and this stock seems to by capable of defying gravity;" says Mike Turner.

The editor of Trade of the Week explains, "The company, based in Foster City, California, has just about everything that I look for in a company and, by extension, its stock.

"True, the biotech sector cannot completely ignore the broader markets, but when a fundamentally and technically strong stock like this bubbles to the surface, I do not want to ignore it.

Continue reading Gilead Sciences (GILD): Defying Gravity

Gilead Sciences (GILD): Defying Gravity originally appeared on BloggingStocks on Fri, 22 Oct 2010 10:00:00 EST. Please see our terms for use of feeds.

"Isis Pharmaceuticals (ISIS) as been a leader in genomics-based drug research since the late 1990s and has amassed an impressive intellectual property portfolio," notes biotech specialist John McCamant.

The editor of The Medical Technology Stock Letter explains, "ISIS has successfully applied their technology to take advantage of the emergence of new genetic information. More specifically, and most important for investors, has been the ability to prolifically patent their discoveries.

"Their proprietary technologies include methods of screening drug candidates, chemical modification of the drugs to improve their efficacy, safety and biostability and methods for the manufacture of DNA and RNA-based therapeutics.

Continue reading Isis Pharmaceuticals (ISIS): Profits in the Human Genome

Isis Pharmaceuticals (ISIS): Profits in the Human Genome originally appeared on BloggingStocks on Thu, 29 Jul 2010 13:00:00 EST. Please see our terms for use of feeds.

Continue reading OncoGenex (OXGI) Targets Prostate Cancer

OncoGenex (OXGI) Targets Prostate Cancer originally appeared on BloggingStocks on Tue, 13 Apr 2010 13:40:00 EST. Please see our terms for use of feeds.

Continue reading Biotech Expert Eyes Isis Pharmaceuticals (ISIS)

Biotech Expert Eyes Isis Pharmaceuticals (ISIS) originally appeared on BloggingStocks on Fri, 12 Mar 2010 12:00:00 EST. Please see our terms for use of feeds.

"Geron (GERN) is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes," says Tom Bishop.

In his BI Research advisory he explains, "The company is also a, if not the, world leader in the development of human embryonic stem cell-based therapeutics." Here's his in-deth analysis of the company.

Continue reading Geron (GERN): 'First in Class' in Stem Cell Research

Geron (GERN): 'First in Class' in Stem Cell Research originally appeared on BloggingStocks on Fri, 15 Jan 2010 13:00:00 EST. Please see our terms for use of feeds.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Our top stock pick for 2010 is ImmunoGen (IMGN)," says biotech specialist John McCamant.

In his The Medical Technology Stock Letter, he explains, "The company's potent cancer-cell killing antibodies were developed for targeted delivery to tumor cells."

Continue reading Top Picks for 2010: ImmunoGen (IMGN)

Top Picks for 2010: ImmunoGen (IMGN) originally appeared on BloggingStocks on Fri, 25 Dec 2009 14:00:00 EST. Please see our terms for use of feeds.

"Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe.

The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing Quad, the first-ever, four-in-one AIDS pill.

"The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead's highest-grossing business. This segment has held up through the recession; in the second quarter product sales for the antiviral franchise grew 26% from a year ago to $1.41 billion.

Continue reading Gilead (GILD): New potential in 4-in-1 HIV drug

Gilead (GILD): New potential in 4-in-1 HIV drug originally appeared on BloggingStocks on Thu, 05 Nov 2009 13:10:00 EST. Please see our terms for use of feeds.

"Sangamo BioSciences (NASDAQ: SGMO) has again received significant scientific validation for its proprietary technology," says biotech expert John McCamant.

In The Medical Technology Stock Letter, he explains, ""Part of what has gotten investors so excited about stem cells was the concept that some day scientists would be able to create 'personalized' stem cell types for individual therapy. We believe that this is the break that was needed to realize the potential of stem cell therapy."

"Stem cells differ from other cell types in two fundamental ways. First, they are unspecialized cells capable of renewing themselves through cell division.

"Second, under certain conditions, they can be induced to become tissue- or organ-specific cells with special functions.

Continue reading Sangamo (SGMO): Progress in adult stem calls?

Sangamo (SGMO): Progress in adult stem calls? originally appeared on BloggingStocks on Fri, 02 Oct 2009 11:30:00 EST. Please see our terms for use of feeds.

"Gilead Sciences (NASDAQ: GILD), one of the world's largest biotechs, is a stock for all seasons," say growth expert Alexander Green.

The investment director for The Oxford Club explains, "It's a fine company with a solid balance sheet, a recession-proof business and excellent growth prospects."

"Gilead focuses on three main areas, including cardiovascular conditions and respiratory diseases. (Many may have taken its anti-influenza drug Tamiflu, Letairis to treat hypertension, or Macugen to treat macular degeneration.)

Continue reading Gilead (GILD): 'A stock for all seasons'

Gilead (GILD): 'A stock for all seasons' originally appeared on BloggingStocks on Fri, 25 Sep 2009 13:00:00 EST. Please see our terms for use of feeds.

In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.

"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.

"However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene.

Continue reading Celgene (CELG): Cancer progress boosts biotech

Celgene (CELG): Cancer progress boosts biotech originally appeared on BloggingStocks on Wed, 19 Aug 2009 14:00:00 EST. Please see our terms for use of feeds.

This post is part of a 12-article feature on the best bets for investing in China. To see all the other recommendations in this special report, click here.

"One Chinese sector being relatively ignored by Wall Street is the biotech industry," notes Keith Fitz-Gerald. In The New China Trader, he looks to a biotech speculation -- Sinovac (AMEX: SVA).

"The government knows that the wheels could fall off the bike rather quickly if average Chinese citizens begin to see a dramatic reversal in their health and happiness.

Continue reading Sinovac (SVA): Chinese biotech bet

Sinovac (SVA): Chinese biotech bet originally appeared on BloggingStocks on Mon, 11 May 2009 13:50:00 EST. Please see our terms for use of feeds.

"Illumina (NASDAQ: ILMN) makes the Genome Analyzer, which is the workhorse of the genetic medicine revolution," says growth expert Mike Cintolo in The Cabot Top Ten Report.

"The Illumina Genome Analyzer is used by genomic research centers, academic institutions, agriculture and livestock companies, pharmaceutical companies, clinical research organizations and biotechnology companies all over the world.

"In the fourth quarter of 2008, for example, the company launched the In? nium HD HumanCytoSNP-12 BeadChip, a 12 sample BeadChip priced as low as $125 per sample that enables researchers to analyze nearly 300,000 genetic markers per sample.

Continue reading Illumina (ILMN): Genetic workhorse

Illumina (ILMN): Genetic workhorse originally appeared on BloggingStocks on Tue, 24 Mar 2009 14:50:00 EST. Please see our terms for use of feeds.

In The Oberweis Report, growth expert Jim Oberweis. Jr. sees upside for risk-oriented investors in two diagnostics firms: Myriad Genetics (NASDAQ: MYGN) and Thoratec (NASDAQ: THOR).

"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women's health.

"The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers.

Continue reading Diagnostics duo: Myriad (MYGN) and Thoratec (THOR)

Diagnostics duo: Myriad (MYGN) and Thoratec (THOR) originally appeared on BloggingStocks on Tue, 17 Mar 2009 10:30:00 EST. Please see our terms for use of feeds.

As an investor, I hate crowds. If a stock or sector that I like attracts a crowd, I know it is time to leave. As they say, the sheep are usually the buyers at the top.

Now, we need sheep to help drive prices of our holdings higher, but at some point it is time to jettison. Nothing goes up forever, and the best signal I have found over the years is to sell when the sheep are buying.

This year the sheep are being told to buy the biotechnology sector.

That advice may be a bit late in coming. 2008 was a disastrous year, but biotechnology did very well. It is that performance that is now attracting the sheep.

Continue reading Don't be a sheep -- beware of biotech (VPHM)

Don't be a sheep -- beware of biotech (VPHM) originally appeared on BloggingStocks on Mon, 09 Feb 2009 18:00:00 EST. Please see our terms for use of feeds.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Biogen Idec (NASDAQ: BIIB) -- which has a highly effective though risky treatment for multiple sclerosis called Tysabri -- is our top pick for 2009," says analyst Richard Moroney.

The editor of Dow Theory Forecasts, an advisory that has been published for more than 50 years, explains, "Despite superior growth prospects, the Tysabri concerns have kept Biogen's shares under pressure.

"In the past two months, consensus profit estimates have crept upwards for Biogen Idec. Per-share profits are expected to climb 33% in 2008 and 9% in 2009. Over the next five years, profits are expected to climb 12% annually. Two factors support this outlook.

"First, Biogen plows nearly a third of its revenue into research and development, raising expectations of a fertile lineup of new drugs. Second, there's Tysabri, a highly effective though risky treatment for multiple sclerosis.

Continue reading Top Stock Picks '09: Biogen Idec (BIIB)

Top Stock Picks '09: Biogen Idec (BIIB) originally appeared on BloggingStocks on Mon, 12 Jan 2009 08:00:00 EST. Please see our terms for use of feeds.

This post is part of a special annual report -- Top Stock Picks '09 -- in which TheStockAdvisors.com asked 75 leading newsletter advisors to select their favorite investment for the new year.

"Emergent BioSolutions (NYSE: EBS) -- my top 2009 pick -- makes the only FDA-licensed vaccine for the prevention of anthrax," says Timothy Lutts in his The Cabot Stock of the Month.

"Located in Rockville, Maryland, the company is currently filling a $448 million government order for 18.75 million doses, and in October, the U.S. government contracted to purchase 14.5 million additional doses valued at up to $404 million, to add to the Strategic National Stockpile.

"The vaccine is named BioThrax, and it accounts for 97% of the revenues of Emergent BioSolutions. However, the company has a full pipeline including two 'next generation' anthrax vaccines.

"Also in development are two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic (botulinum is the nasty form of Botox), an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy and a chlamydia vaccine.

Continue reading Top Stock Picks '09: Emergent BioSolutions (EBS)

Top Stock Picks '09: Emergent BioSolutions (EBS) originally appeared on BloggingStocks on Sat, 10 Jan 2009 11:00:00 EST. Please see our terms for use of feeds.